Sunday, 23 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com

BIOSENIC Stock Is 9% Up At Session Start On Thursday

Loading stream...

(VIANEWS) - Shares of BIOSENIC (BEL 20: BIOS.BR) jumped 9.06% to €0.14 at 10:10 EST on Thursday, after four sequential sessions in a row of losses. BEL 20 is jumping 0.89% to €3,662.18, after five consecutive sessions in a row of losses. This seems, up to now, a somewhat bullish trend trading session today.

About BIOSENIC

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.

Volatility

BIOSENIC's last week, last month's, and last quarter's current intraday variation average was a negative 4.78%, a negative 1.77%, and a positive 6.31%.

BIOSENIC's highest amplitude of average volatility was 4.78% (last week), 6.15% (last month), and 6.31% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC's stock is considered to be overbought (>=80).

Volume

Today's last reported volume for BIOSENIC is 104518 which is 64.37% below its average volume of 293419.

More news about BIOSENIC (BIOS.BR).